SAM
RYTM icon

Silvercrest Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Silvercrest Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.15M Buy
73,432
+26,545
+57% +$2.4M 0.05% 390
2026
Q1 		$4.08M Buy
46,887
+12,760
+37% +$1.24M 0.03% 453
2025
Q4 		$3.65M Buy
34,127
+43
+0.1% +$4.56K 0.03% 468
2025
Q3 		$3.44M Sell
34,084
-14,691
-30% -$1.36M 0.02% 473
2025
Q2 		$3.08M Buy
+48,775
New +$2.99M 0.02% 491

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Silvercrest Asset Management's RYTM Position: Q2 2026 in Review

Silvercrest Asset Management increased its Rhythm Pharmaceuticals (RYTM) stake by 57% in Q2 2026, buying an estimated $2.4M and bringing the position to 73,432 shares worth $8.15M. The position accounts for 0.05% of the portfolio, ranked #390.

Silvercrest Asset Management first reported a position in RYTM in Q2 2025 and has held it in 5 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Silvercrest Asset Management held 73,432 shares of Rhythm Pharmaceuticals worth $8.15M as of Q2 2026.
  • Silvercrest Asset Management bought 26,545 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $2.4M.
  • Rhythm Pharmaceuticals made up 0.05% of Silvercrest Asset Management's portfolio in Q2 2026, its #390 holding.
  • Silvercrest Asset Management first reported a position in Rhythm Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.